Your browser doesn't support javascript.
loading
Research and development of a silicone letrozole-releasing device to control reproduction in cattle.
Zwiefelhofer, E M; Davis, B M; Adams, G P.
Afiliação
  • Zwiefelhofer EM; Department of Veterinary Biomedical Sciences, Western College of Veterinary Medicine University of Saskatchewan, Saskatoon, Saskatchewan, S7N 5B4, Canada.
  • Davis BM; Department of Veterinary Biomedical Sciences, Western College of Veterinary Medicine University of Saskatchewan, Saskatoon, Saskatchewan, S7N 5B4, Canada.
  • Adams GP; Department of Veterinary Biomedical Sciences, Western College of Veterinary Medicine University of Saskatchewan, Saskatoon, Saskatchewan, S7N 5B4, Canada. Electronic address: gregg.adams@usask.ca.
Theriogenology ; 146: 104-110, 2020 Apr 01.
Article em En | MEDLINE | ID: mdl-32070830
ABSTRACT
Two experiments were conducted to test the effectiveness of a silicone matrix as an intravaginal drug delivery device for letrozole, an aromatase inhibitor used for synchronization protocols in cattle. A wax dip-coat formulation of the intravaginal device used in previous studies was effective in releasing letrozole but was cumbersome to manufacture and deploy, resulting in unwanted variation in drug delivery and circulating concentrations of letrozole. In Experiment 1, a 3 × 3 design was used to test the release kinetics of letrozole from silicone in vitro. Silicone was mixed with 3 different letrozole drug loads (5%, 10%, 15%) and 3 different mineral oil loads (5%, 10%, 15%), and letrozole release into 62.5% ethanol was compared with the wax dip-coat formulation (positive control) by UV spectrophotometry. Letrozole was released from silicone in a dose-dependent manner, with no effect of mineral oil. Release kinetics were then examined in vivo (Experiment 2) in nulliparous beef heifers assigned randomly to six groups (n = 6/group) and given either a large surface area (LSA) with 5% or 15% drug load, a standard surface area (SSA) intravaginal silicone device impregnated with 10% or 15% drug load, a wax dip-coat device (positive control), or a blank device (negative control). Devices were inserted on Day 3 (Day 0 = ovulation) until Day 11. Blood samples were collected at 0, 30 min, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h, and twice daily until Day 11 to determine letrozole plasma concentrations by LC-MS/MS and estradiol plasma concentrations by radioimmunoassay The ovaries were examined once daily from Day 3-13 by ultrasonography to determine follicular and luteal responses to treatment. Letrozole plasma concentrations were higher in heifers given a device with an LSA vs SSA (P < 0.05). Plasma concentrations of estradiol decreased the most in heifers given the 15% LSA device (P = 0.06). The interval between emergence of successive follicular waves was longest (P < 0.05) in the positive control and the 15% LSA groups. As well, the diameter profiles of the dominant follicle and the corpus luteum were largest (P < 0.01) in the positive control and 15% LSA groups. In conclusion, letrozole was released from a silicone matrix in vitro in a dose-dependent manner, and the 15% LSA devices achieved target effects on ovarian function. Results may be used to manufacture a silicone intravaginal device for delivering aromatase inhibitors in a novel synchronization protocol for cattle.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Silicones / Bovinos / Letrozol Tipo de estudo: Guideline Limite: Animals Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Silicones / Bovinos / Letrozol Tipo de estudo: Guideline Limite: Animals Idioma: En Ano de publicação: 2020 Tipo de documento: Article